Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

Immunocore's $130M series B will take lead candidate through pivotal Phase II

Nearly five years after Immunocore raised what was then the largest-ever European venture round at $320 million, the company has raised a fresh $130 million from a syndicate featuring seven new investors to both advance and broaden the biotech’s pipeline of T cell receptor bispecifics.

Growth equity investor General

Read the full 483 word article

How to gain access

Continue reading with a
two-week free trial.